July 30, 2020
IBRI IN THE NEWS: IBRI Technologies Lead to Handheld Analyzing Device
Indianapolis - The Indiana Biosciences Research Institute (IBRI) is marking a milestone: the team is licensing its first technology, and as a result, giving birth to a startup based in...
July 25, 2020
IBRI RESEARCH PUBLISHED: Targeting Polyamine Biosynthesis to Stimulate Beta Cell Regeneration in Zebrafish
Type 1 diabetes (T1D) is a disease characterized by destruction of the insulin-producing beta cells. Currently, there remains a critical gap in our understanding of how to reverse...
July 01, 2020
IBRI RESEARCH PUBLISHED: Insulin Resistance Does Not Impair Mechanical Overload-Stimulated Glucose Uptake, but Does Alter the Metabolic Fate of Glucose in Mouse Muscle
Skeletal muscle glucose uptake and glucose metabolism are impaired in insulin resistance. Mechanical overload stimulates glucose uptake into insulin-resistant muscle; yet the mechanisms underlying this beneficial effect remain...
June 24, 2020
IBRI RESEARCH PUBLISHED: Adiponectin receptor fragmentation in mouse models of type 1 and type 2 diabetes
The protein hormone adiponectin regulates glucose and fatty acid metabolism by binding to two PAQR-family receptors (AdipoR1 and AdipoR2). Both receptors feature a C-terminal segment which is released...
June 15, 2020
IBRI IN THE NEWS: Biosciences Institute Develops Diagnosis Technologies
INDIANAPOLIS - The Indiana Biosciences Research Institute in Indianapolis has completed development of two technologies it says could diagnose diseases faster and with more accuracy. The IBRI says its BioMEMs...
June 11, 2020
IBRI Develops Technologies that Help to Diagnose Diseases Faster, More Accurately
INDIANAPOLIS, IND. - The Indiana Biosciences Research Institute (IBRI), a leading independent, industry-inspired applied research institute, is pleased to announce that it has completed development of two technologies – BioMEMs...
June 09, 2020
IBRI and TBH Creative Win Gold Aster Award
We were pleased to partner with TBH Creative to move our 2018 Annual Report from print to online. TBH Creative took the PDF and transformed it into its own microsite...
June 03, 2020
IBRI RESEARCH PUBLISHED: Pre-clinical Evaluation of TYK2 Inhibitors for Human Beta Cell Protection in Type 1 Diabetes
Aims: Type 1 diabetes (T1D) is a chronic autoimmune disease leading to progressive loss of pancreatic beta cells. Interferon (IFN)-α plays a critical role in the crosstalk between...
May 29, 2020
IBRI IN THE NEWS: Pushing Hard for a COVID-19 Vaccine
The race is on.
Around the world, more than 80 vaccine projects are under development by pharmaceutical companies and university research laboratories scrambling to find a way to slow...
May 26, 2020
New Research Identifies Two Classes of Drugs that Could be Re-purposed for the Early Treatment of T1D
INDIANAPOLIS - Researchers from the Indiana Biosciences Research Institute (IBRI), a leading independent, industry-inspired applied research institute, and Université Libre de Bruxelles (ULB) Center for Diabetes Research, identified two classes...
1 2 3 4 5 ... Last